Long Covid remains poorly understood and follow-up studies play an integral role in establishing an epidemiological and ...

Hoth Therapeutics has reported interim data from a trial of HT-001, a drug designed for treating pruritus associated with ...

Genesis has gained US Food and Drug Administration (FDA) clearance on an Investigational New Drug (IND) application for a ...

More than just a tool for advancing pipelines, trial efficiency is the name of the game when it comes to synthetic control ...

Accent Therapeutics has dosed the first subject in an open-label Phase I/II trial of ATX-295, an oral kinesin family member ...

BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for ...

Neuren has confirmed the primary goals for its double-blind, single Phase III pivotal trial of NNZ-2591 in treating PMS for ...

Amgen's global Phase III DeLLphi-304 trial of Imdelltra has met its primary endpoint at a planned interim analysis for ...

With trial costs rising over the past decade and concerns they’ll keep climbing, companies are seeking ways to manage ...

Corxel Pharmaceuticals has received investigational new drug (IND) application clearance from the US FDA for the trial of CX11 for obesity.

Pheast Therapeutics has treated the first subject in a multi-centre Phase I trial for PHST001, aimed at treating advanced solid tumours.

Vantage Biosciences has dosed the first subject in the randomised Phase II trial of oral therapy VX-01 to treat NPDR.